Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD compared with SGLT-2 inhibitors.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed obesity management, offering substantial weight loss and metabolic benefits. This review examines their expanding role, ...

GLP-1 receptor agonists (GLP-1) are medicines that lower blood glucose levels and may also have beneficial effects on high blood pressure and obesity, and decrease the chances of death, heart attack, ...

Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Individuals with type 2 diabetes mellitus (T2DM) receiving glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy do not have an increased risk for thyroid tumors, according to study findings ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according to a scientific statement.

While GLP-1 RA use was associated with a lower risk of delirium in the early treatment period, this advantage disappeared with long-term use and metformin remained associated with superior survival.

While GLP-1 RA use was associated with a lower risk of delirium in the early treatment period, this advantage disappeared with long-term use and metformin remained associated with superior survival.

Innovent Biologics Inc. announced June 27 that it gained National Medical Products Administration’s (NMPA) approval of mazdutide as a new weight loss therapy for obese or overweight patients in China.